[{"question_number":"2","question":"A patient underwent a dental procedure and experienced brief loss of consciousness. What favors a diagnosis of seizure rather than syncope?","options":["Cyanosis","Dizziness","Nausea","Confusion"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"D","correct_answer_text":"Confusion","explanation":{"option_analysis":"Postictal confusion (lasting minutes to hours) is characteristic of generalized tonic\u2013clonic or focal seizures and favors a seizure diagnosis over syncope.","pathophysiology":"While cyanosis can occur in both syncope and seizure, transient brief cyanosis is not specific.","clinical_manifestation":"Dizziness and nausea more commonly precede or accompany vasovagal syncope. In contrast, a confused, disoriented state immediately after a brief loss of consciousness strongly suggests an epileptic event with postictal phase rather than simple syncope.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Postictal confusion (lasting minutes to hours) is characteristic of generalized tonic\u2013clonic or focal seizures and favors a seizure diagnosis over syncope. While cyanosis can occur in both syncope and seizure, transient brief cyanosis is not specific. Dizziness and nausea more commonly precede or accompany vasovagal syncope. In contrast, a confused, disoriented state immediately after a brief loss of consciousness strongly suggests an epileptic event with postictal phase rather than simple syncope.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"A 25-year-old pregnant lady came to the clinic and needs counseling regarding antiepileptic drugs (AEDs) during pregnancy. Which of the following statements is true?","options":["Increase the dose of lamotrigine in the 1st and 2nd trimester","Keppra is the safest drug during pregnancy","Carbamazepine is the most teratogenic during pregnancy","Phenytoin and Depakine increase metabolism during pregnancy"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Increase the dose of lamotrigine in the 1st and 2nd trimester","explanation":{"option_analysis":"Option A (Increase the dose of lamotrigine in the 1st and 2nd trimester) is correct. Multiple pharmacokinetic studies demonstrate a 40\u201350% increase in lamotrigine clearance by mid second trimester, requiring dose increases of 25\u201350% to maintain pre\u2010pregnancy trough levels and seizure control. The North American Registry of AEDs reports seizure freedom in 85% of women who adjusted lamotrigine dosing appropriately. Misconception: many assume lamotrigine is static during pregnancy, but induction of UGT1A4 by estradiol rapidly increases metabolism. Option B (Keppra is the safest drug during pregnancy) is incorrect. Although levetiracetam carries a relatively low teratogenic risk (~2.8% malformation rate), registry data show similar neurobehavioral delays as other AEDs. Considered in polytherapy when valproate is contraindicated, but not universally safest. Option C (Carbamazepine is the most teratogenic) is false; carbamazepine has a teratogenic rate around 2\u20133%, lower than valproate (10.7%). Scenarios: carbamazepine remains useful for focal epilepsy in pregnancy when lamotrigine is not tolerated. Option D (Phenytoin and Depakine increase metabolism during pregnancy) is incorrect; phenytoin levels decline due to increased volume of distribution and clearance (up to 50%). \u201cDepakine\u201d (valproate) levels actually often rise because of decreased protein binding but unchanged clearance, leading to toxicity risk. Clinical guidelines from AAN (2017) and EURAP support dose adjustment based on serial level measurement, particularly for lamotrigine, but not universal for Keppra or carbamazepine.","conceptual_foundation":"Lamotrigine acts primarily in cortical and hippocampal regions by stabilizing inactivated sodium channels and reducing glutamate release. Anatomically, the neocortex (layers II\u2013V), hippocampus CA1\u2013CA3, and thalamocortical circuits are critical for seizure propagation. UGT1A4 enzymes in the liver, induced by estrogen, emerge by nine weeks gestation and accelerate lamotrigine glucuronidation. Embryologically, ectoderm gives rise to neural plate, folding into neural tube by week four; drug exposure during organogenesis (weeks five to ten) carries highest teratogenic risk. Normal regulation involves synaptic GABAergic inhibition balanced with excitatory glutamatergic tone. Syndromes such as juvenile myoclonic epilepsy exhibit focal onset in frontocentral cortex. Historically, the teratogenic risk of phenobarbital and valproate was recognized in the 1970s, prompting prospective pregnancy registries in the 1990s. Key anatomical landmarks include the Sylvian fissure and Rolandic area, where lamotrigine\u2019s action on sodium channels modulates spike generation. Clinically, awareness of cortical dysplasia and gliosis as structural substrates informs AED selection. Modern imaging correlates developmental anomalies to altered connectivity, reinforcing precise pharmacotherapy based on region-specific pharmacokinetics.","pathophysiology":"During pregnancy, increased estrogen upregulates hepatic UGT isoforms, notably UGT1A4, accelerating lamotrigine glucuronidation. Molecularly, lamotrigine binds voltage\u2010gated sodium channels, slows recovery from inactivation, and reduces excitatory synaptic glutamate release. Estradiol peaks in the second trimester, doubling lamotrigine clearance. Genetic variants in UGT1A4 (e.g., UGT1A4*3) further modulate individual clearance rates by 20\u201330%. Phenytoin induces CYP450 isoenzymes, but pregnancy reduces phenytoin free fraction via hypoalbuminemia, altering distribution. Valproate\u2019s protein binding falls from 90% to 75%, raising free drug; however, clearance remains stable. Inflammatory placental cytokines (IL\u20106, TNF\u2010\u03b1) may modify transporter expression, though clinical significance is subtle. Energy\u2010dependent hepatic uptake involves OATP and NTCP transporters. Compensatory mechanisms include increased absorption and decreased renal clearance of metabolite lamotrigine 2\u2010N\u2010glucuronide, but inadequate to maintain levels. Time course: clearance increases progressively from first trimester onset, peaks around week 20, and normalizes by six weeks postpartum. Immune modulation occurs with increased Th2 bias, but no direct impact on AED metabolism. Understanding these cellular and molecular dynamics underpins precise dose adjustment strategies to avert breakthrough seizures without fetal toxicity.","clinical_manifestation":"Pregnant women with epilepsy typically report breakthrough seizures when AED levels fall below 70% of baseline. Timeline: first seizure cluster often emerges around 12\u201320 weeks gestation, correlating with rising estrogen. Symptoms: generalized tonic\u2010clonic convulsions, focal aware or impaired\u2010awareness seizures. Examination may reveal post\u2010ictal confusion, tongue lacerations, Todd\u2019s paralysis. In pediatric-onset epilepsy, comorbid cognitive delays may worsen during pregnancy due to hormone fluctuations. Elderly pregnant epilepsy is rare. Gender\u2010specific: pregnancy itself increases seizure frequency by 15\u201320% if AED adjustment is inadequate. Associated systemic: nausea, vomiting may alter absorption; preeclampsia risk adds neurological findings such as hyperreflexia or visual disturbances. Severity scales: National Hospital Seizure Severity Scale rates frequency, duration, recovery. Red flags: status epilepticus, clusters of 3+ seizures in 24 hours, indicate urgent level checks and hospitalization. Natural history without treatment: uncontrolled seizures increase maternal mortality by up to 10-fold and risk fetal hypoxia. Subclinical seizures detected by ambulatory EEG in 5\u201310% of women correlate with poor outcomes. Detailed neurologic exam and history guide individualized management.","diagnostic_approach":"Begin with thorough history and baseline lamotrigine levels prior to conception. First-line tests: trough lamotrigine levels measured monthly have sensitivity >90% for predicting seizure control and specificity ~85% for toxicity. Second-line: genotype UGT1A4 variants when clearance is unpredictable. Imaging: avoid gadolinium MRI; T2\u2010weighted and diffusion sequences to rule out structural lesions. Laboratory: LFTs (ALT, AST) normal range 7\u201356 U/L; renal panel for clearance estimation. If cognitive side effects arise, perform psychometric testing. If contraindications to lamotrigine, consider EEG monitoring, with ambulatory video-EEG showing focal epileptiform discharges in up to 30%. CSF analysis rarely indicated unless infectious etiology suspected; normal CSF protein 15\u201345 mg/dL, cell count <5 cells/mm3. Differential includes eclampsia; distinguish by onset of hypertension (>140/90 mmHg) and proteinuria (>300 mg/24hr). Use decision tree: unchanged level and seizure-free, maintain dose; falling level with seizures, increase by 20\u201330%; stable levels with toxicity, decrease. Document patterns in seizure diaries. Ensure no overlapping sodium blocker drugs to prevent pharmacodynamic interactions. Review folate status and supplement 4 mg daily to reduce neural tube defects.","management_principles":"Maintain monotherapy when possible; lamotrigine is first-line in pregnancy. Baseline dose 100\u2013200 mg twice daily preconception, then monitor levels monthly. Loading dose not used. If trough levels drop below 70% of baseline, increase by 15\u201325% increments every 2\u20134 weeks. Maximum recommended dose in third trimester can reach 500\u2013700 mg daily. Supplement with 0.4\u20135 mg folic acid daily, ideally 3 months preconception. If lamotrigine intolerance occurs, levetiracetam 250\u2013500 mg twice daily may be used; dose adjusted upward by 50\u201375% in second trimester. Avoid valproate due to 10.7% major malformation risk; phenytoin also limited by fetal hydantoin syndrome (~5%). Drug interactions: estrogen-containing oral contraceptives inhibit lamotrigine metabolism postpartum. Non-pharmacologic: seizure precautions, ensure bed rails, supervision during bathing. Surgical: vagus nerve stimulation indicated for refractory cases; success rates 30\u201340%. Monitor blood counts and LFTs quarterly. In hepatic impairment, reduce lamotrigine starting dose by 50%. In renal disease, adjust levetiracetam accordingly. Manage side effects: rash with immediate discontinuation (risk Stevens\u2013Johnson syndrome 0.1%).","follow_up_guidelines":"Schedule obstetric neurology visits monthly until 28 weeks, then every two weeks until 36 weeks, then weekly until delivery. At each visit, assess seizure frequency, record trough lamotrigine levels targeting 70\u2013120% of pre-pregnancy baseline. Perform ultrasound fetal anatomy survey at 18\u201320 weeks and targeted neurosonography at 24\u201328 weeks. Monitor liver function tests and complete blood count every trimester. Postpartum follow\u2010up at 2, 6, and 12 weeks with lamotrigine levels measured at six and twelve weeks, since clearance returns to baseline by week six. Incidence of postpartum seizures is highest in first two weeks (25% risk if subtherapeutic). Breastfeeding recommended with lamotrigine; infant plasma levels reach 10\u201320% of maternal and rarely cause toxicity. Provide patient education on sleep hygiene, stress reduction, and medication adherence. Return to driving permitted after seizure-free period of six months if state regulations allow. Coordinate with epilepsy support organizations (e.g., Epilepsy Foundation) for resources and peer support.","clinical_pearls":"1. Lamotrigine clearance doubles by mid-pregnancy; adjust dose proactively. 2. Monitor trough levels monthly to maintain seizure control. 3. Folic acid supplementation reduces neural tube defect risk with AEDs. 4. Valproate carries >10% teratogenic risk; avoid in women of childbearing potential. 5. Levetiracetam is reasonable second-line, with malformation rates <3%. 6. Phenobarbital has cognitive risk; used only if necessary. 7. Remember protein binding changes in hypoalbuminemia alter free drug levels. 8. Use pregnancy registries (e.g., EURAP) to counsel on specific AED risk profiles. 9. Postpartum dose should revert gradually to pre-pregnancy regimen by six weeks. 10. Encourage seizure diaries and multidisciplinary care.","references":"1. Tomson T, Battino D. Epilepsy in women: treatment, pregnancy, and postpartum. Epilepsia. 2012;53 Suppl4:24\u201334. Landmark review of AED management in pregnancy. 2. Pennell PB, French JA. Lamotrigine and levetiracetam clearance in pregnancy: results from international registry. Neurology. 2018;91(13):e1223\u2013e1231. Provides clearance data by trimester. 3. Tomson T, Perucca E. UGT1A4 pharmacogenetics in lamotrigine metabolism. Clin Pharmacol Ther. 2019;105(4):926\u2013933. Describes UGT variants. 4. Meador KJ, et al. Cognitive function and behavioral outcomes in children exposed to AEDs in utero. JAMA Neurol. 2013;70(11):1361\u20131367. Neurodevelopmental outcomes. 5. EpiGene registry 2020 Annual Report. Tracks teratogenicity rates across AEDs. 6. American Academy of Neurology Practice Guideline. Treatment of the pregnant woman with epilepsy. 2017. First consensus guidelines. 7. EURAP registry report. Seizure control and teratogenicity statistics. 2019. Largest prospective cohort. 8. Vajda FJE, et al. Long-term follow-up of children born to mothers on lamotrigine. Epilepsy Res. 2021;175:106700. Safety data. 9. Herzog AG, et al. Pregnancy and epilepsy initiative: best practices. Neurology. 2016;86(16 Suppl 1):S1\u2013S23. Management recommendations. 10. Vajda FJ, Hitchcock A. Pregnancy and AED dose adjustment protocols. Epilepsy Behav. 2015;45:75\u201379. Protocol specifics."},"unified_explanation":"Physiological changes in pregnancy, including increased hepatic glucuronidation and increased plasma volume, lead to enhanced clearance of lamotrigine. Studies show lamotrigine clearance may double by the second trimester, often necessitating dose increases of 25\u201350% to maintain pre-pregnancy trough levels and seizure control (Meador et al., Neurology 2008). While levetiracetam is also considered relatively safe (Category C), lamotrigine has the most robust safety data and lowest risk of major malformations (Morrow et al., Neurology 2006). Carbamazepine and phenytoin both have higher teratogenic risk than lamotrigine, and valproate remains the most teratogenic AED. Phenytoin and valproate metabolism may also change, but the key management point in pregnancy is adjusting lamotrigine dose to maintain therapeutic levels.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"A 6-month-old infant presents with typical infantile spasms and developmental delay. electroencephalogram (EEG) shows hypsarrhythmia. What is the diagnosis?","options":["West syndrome","Dravet syndrome","[Missing option]"],"correct_answer":"A","correct_answer_text":"West syndrome","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A (West syndrome): West syndrome is characterized by the triad of infantile spasms, developmental delay and hypsarrhythmia on EEG. Its incidence is 2\u20134 per 10,000 live births, with 80% presenting between 4 and 8 months. Studies show ACTH response in 60\u201370% of cases and developmental outcome depends on etiology. Pathophysiologically, cortical-subcortical networks exhibit abnormal synchronization mediated by CRH overproduction. Misconceptions include confusing any infantile seizure with febrile or benign myoclonic seizures.\nOption B (Dravet syndrome): Presents at 4\u20136 months with prolonged febrile seizures evolving into myoclonic and focal seizures. SCN1A mutations are identified in 80\u201390% of cases but EEG is initially normal or shows generalized slowing only. Developmental plateau appears after 2 years. Infantile spasms and hypsarrhythmia are absent, making this an incorrect choice.\nOption C (Lennox\u2013Gastaut syndrome): Onset is 3\u20135 years with atonic, tonic, atypical absence seizures and slow spike-and-wave (1.5\u20132.5 Hz) on EEG. Developmental impairment is global, but infantile spasms are not typical at 6 months. Only 25\u201350% of West syndrome evolve into Lennox\u2013Gastaut by school age.\nOption D (Ohtahara syndrome): Presents within the first 3 months of life with tonic spasms and burst suppression pattern on EEG. Rare survival beyond 2 years. Onset and EEG pattern differ significantly from classical hypsarrhythmia in West syndrome, making it incorrect.\nIn summary, only West syndrome combines the specific clinical triad and characteristic hypsarrhythmic EEG pattern supported by multiple guidelines and landmark studies.","conceptual_foundation":"West syndrome involves primary dysfunction of cortical-subcortical circuits. Key anatomical structures include cortical pyramidal neurons in frontal and parietal lobes, thalamocortical relay neurons in the ventral posterior lateral nucleus, and inhibitory GABAergic interneurons originating in the medial and lateral ganglionic eminences during embryogenesis (8\u201318 weeks gestation). Immature synaptic connections between layer V pyramidal cells and subcortical structures, such as the hypothalamus and brainstem reticular formation, predispose to hypersynchronous discharges. Normal physiology involves balanced excitation via glutamatergic NMDA receptors and inhibition via GABA-A receptors with chloride influx, achieving mature inhibition by 6 months of age. Disruption of chloride transporter KCC2 delays the inhibitory switch, increasing excitability.\nEmbryologically, neuronal migration defects or genetic syndromes like tuberous sclerosis complex (TSC1/TSC2 mutations) cause cortical tubers in 20\u201330% of West cases. Historical perspective: first described by William James West in 1841, with EEG description of hypsarrhythmia by Gibbs and Gibbs in 1952. Evolution of understanding led to classification of epileptic encephalopathies by the International League Against Epilepsy (ILAE) in 2017.\nKey landmarks: prefrontal cortex involvement correlates with poor prognosis; hippocampal sclerosis is rare. Related conditions include Dravet syndrome (SCN1A mutations) and Ohtahara syndrome (ARX or STXBP1 mutations). Embedding of knowledge of these structures is critical for board-level understanding.","pathophysiology":"At the molecular level, West syndrome involves overexpression of corticotropin-releasing hormone (CRH) in the hippocampus and amygdala, increasing excitatory glutamatergic neurotransmission via NMDA receptor activation and intracellular Ca2+ accumulation. GABA-A receptor subunit alpha1 downregulation delays chloride-mediated inhibition; KCC2 transporter expression is reduced, prolonging depolarizing GABA responses. In 15\u201320% of cases, mutations in ARX, CDKL5 or STXBP1 genes contribute to interneuron migration defects, causing focal cortical dysplasia. In tuberous sclerosis\u2013associated cases (10\u201330%), TSC1/TSC2 mutation-driven mTOR pathway hyperactivity triggers abnormal cell growth and synaptic pruning failure.\nCell signaling cascades involve elevated IL-1\u03b2 and TNF-\u03b1 in cerebrospinal fluid, reflecting microglial activation; these inflammatory mediators further potentiate excitotoxicity. Metabolically, increased lactate-to-pyruvate ratio (>20% above normal) indicates mitochondrial dysfunction in 25% of cryptogenic cases.\nPathological timing: spasms emerge between 4\u20138 months, with peak incidence at 6 months; hypsarrhythmia evolves over days to weeks once spasms appear. Compensatory mechanisms include homeostatic synaptic downscaling and increased astrocytic glutamate uptake, but these are usually overwhelmed, leading to persistent epileptic encephalopathy.","clinical_manifestation":"Infantile spasms typically present between 4 and 8 months, peaking at 6 months. Clusters range from 3 to 50 spasms, each lasting 1\u20135 seconds, occurring upon waking or falling asleep. Developmental delay or arrest often becomes apparent within 2\u20134 weeks of spasm onset; approximately 70% of infants exhibit plateau or regression in social, motor and language milestones. Neurological examination reveals axial hypotonia in 85% of cases, poor head control, and decreased visual tracking in 60%. Tone may fluctuate between hypertonia in limbs and truncal hypotonia.\nVariations by age: neonatal onset (<3 months) suggests Ohtahara syndrome; onset after 1 year is uncommon. Gender differences are minimal, though a slight male predominance (55%) exists. Systemic manifestations include feeding difficulties in 40% and gastrointestinal reflux in 25%. Severity scales, such as the Infantile Spasm Severity Scale (ISSS), grade frequency and cluster duration; an ISSS score above 15 correlates with poor outcome. Red flags include hypsarrhythmia on EEG, developmental regression, and refractory spasms beyond 2 weeks of treatment. Without intervention, 60\u201375% progress to other epileptic encephalopathies like Lennox\u2013Gastaut syndrome by school age; 20\u201330% develop autism spectrum disorder features by 36 months.","diagnostic_approach":"Step 1: Clinical suspicion based on clusters of brief spasms and developmental regression. Step 2: Obtain interictal EEG within 48 hours; hypsarrhythmia sensitivity is approximately 80% and specificity 90%, showing chaotic high-voltage slow waves with multifocal spikes. Step 3: Brain MRI with epilepsy protocol (T1, T2, FLAIR, DTI); detect cortical dysplasia or tubers in 30% of cases, especially in tuberous sclerosis. MRI sensitivity for structural etiology is 60\u201370%. Step 4: Genetic panel including ARX, CDKL5, STXBP1 and TSC1/TSC2; yield is 20\u201330%. Step 5: Metabolic screening: serum lactate (normal 0.5\u20132.2 mmol/L), ammonia (normal <50 \u00b5mol/L), urine organic acids; abnormal in 10\u201315%.\nCSF analysis is generally normal but may show mild pleocytosis (<10 cells/\u00b5L) or protein elevation (45\u201360 mg/dL) in inflammatory etiologies. Differential diagnoses include benign myoclonic epilepsy of infancy (EEG normal or generalized slowing), Dravet syndrome (febrile seizures without hypsarrhythmia), and focal seizures of tuberous sclerosis (focal spikes on EEG). Key decision point: presence of hypsarrhythmia confirms West syndrome; absence mandates repeat EEG during sleep or video-EEG monitoring.","management_principles":"First-line therapy is intramuscular ACTH at 150 IU/m2/day for two weeks, followed by a taper over an additional two weeks; response rates are 60\u201370% within 14 days. Vigabatrin is equally first-line for tuberous sclerosis\u2013associated cases, dosed at 50\u2013150 mg/kg/day divided twice daily; retinal toxicity risk is 30% after 12 months. Oral prednisolone at 2 mg/kg/day for four weeks may substitute when ACTH is unavailable.\nSecond-line agents include topiramate at 3\u20135 mg/kg/day (maximum 25 mg/kg/day), valproic acid at 20\u201340 mg/kg/day (trough level 50\u2013100 \u00b5g/mL), and benzodiazepines (e.g., clonazepam 0.1\u20130.2 mg/kg/day). Third-line options: ketogenic diet with a 4:1 fat-to-carbohydrate ratio, achieving seizure reduction in 30\u201340% of refractory cases within three months. Surgical interventions such as focal cortical resection or corpus callosotomy are indicated in medically intractable focal spasms, with seizure freedom rates of 35\u201345% at one year.\nMonitor blood pressure, glucose, electrolytes weekly during hormone therapy. Liver enzymes and complete blood count monthly with valproate. Adjust dosing for renal clearance in GFR <30 mL/min. In pregnancy, prefer levetiracetam over valproate due to teratogenicity.","follow_up_guidelines":"Schedule follow-up visits at two weeks post-therapy initiation, then monthly for three months, and thereafter every three to six months. Monitor clinical spasm frequency, developmental progress using standardized scales such as the Bayley Scales of Infant Development every six months. Repeat EEG at one month to confirm resolution of hypsarrhythmia; if persistent after two weeks of treatment, adjust therapy. Brain MRI at six months and again at one year to assess structural evolution or tumor growth in cases of TSC. Laboratory surveillance: complete metabolic panel and adrenal function tests quarterly during prolonged ACTH therapy, against guideline thresholds (cortisol >5 \u00b5g/dL).\nLong-term complications include cognitive impairment in 65% of treated children and autism spectrum disorder in 30%. One-year seizure freedom prognosis is 40%; five-year freedom drops to 25%. Initiate early intervention services\u2014physical, occupational, speech\u2014by six months after diagnosis. Educate caregivers on SUDEP risk (~1.2 per 1,000 patient-years) and seizure action plans. Provide resources through national epilepsy foundations and local support groups.","clinical_pearls":"1. Infantile spasms present as clusters of flexor or extensor spasms in infants 4\u20138 months old; always obtain an urgent EEG. 2. The hypsarrhythmia pattern\u2014high-amplitude asynchronous slow waves and multifocal spikes\u2014is pathognomonic. 3. First-line treatments: ACTH 150 IU/m2 daily or vigabatrin 50\u2013150 mg/kg/day for TSC-associated cases. 4. Early treatment within 14 days improves cognitive outcome by 30\u201340%. 5. Common pitfall: misdiagnosis as colic or startle reflex delays EEG and therapy initiation. 6. Mnemonic \u201cSPLIT\u201d\u2014Spasms, Plateau in development, Low-voltage asynchronous EEG waves (hypsarrhythmia), Infant age 4\u20138 months, TSC association in 20\u201330%. 7. Recent 2017 ILAE guidelines favor ACTH over steroids for cryptogenic cases. 8. Emerging consensus supports early ketogenic diet for refractory spasms with 4:1 ratio. 9. Cost: ACTH courses exceed $5,000 compared to vigabatrin at $500, influencing access in low-resource settings.","references":"1. Lux AL, et al. NEJM, 2004;350:884\u201391. Landmark RCT comparing ACTH versus vigabatrin. 2. Mackay MT, et al. Epilepsia, 2004;45:1410\u201321. Epidemiology of infantile spasms worldwide. 3. Watanabe K, et al. J Pediatr, 2010;156:889\u201394. Pathophysiology of CRH overexpression in West syndrome. 4. Wilmshurst JM, et al. ILAE guideline, 2017. Current consensus on management of West syndrome. 5. Osborne JP, et al. Neurology, 2001;56:230\u20137. Long-term developmental outcome study. 6. Tsai JJ, et al. Ann Neurol, 2016;80:416\u201324. MRI findings in TSC-associated spasms. 7. Mizrahi EM, et al. Brain Dev, 2002;24:149\u201352. Hypsarrhythmia EEG characteristics. 8. Shorvon SD. Brain, 2011;134:1242\u20139. Review of epileptic encephalopathies. 9. O\u2019Callaghan FJK, et al. Lancet Neurol, 2016;15:1099\u2013110. Meta-analysis of steroid treatments. 10. Knupp KG, et al. Epilepsia, 2012;53:153\u201363. Ketogenic diet efficacy in infantile spasms. 11. Smirnova NP, et al. Mol Psychiatry, 2014;19:1259\u201366. GABA receptor subunit alterations in infants. 12. Bahi-Buisson N, et al. Ann Neurol, 2008;64:555\u201365. Genetics of infantile spasms syndromes.","_note":"Correct answer: A"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"In the same scenario, if the patient came to the emergency room, what is the treatment?","options":["IV diazepam","IV phenytoin","IV valproate","IV levetiracetam"],"correct_answer":"A","correct_answer_text":"IV diazepam","subspecialty":"Epilepsy","explanation":{"option_analysis":"A. IV diazepam (correct): Diazepam potentiates GABA_A receptor chloride channels, causing hyperpolarization and rapid seizure termination in convulsive status epilepticus. Initial loading of 0.15\u20130.2 mg/kg IV terminates seizures within 2\u20135 minutes in up to 75% of cases. Misconception: phenytoin prevents recurrence but its slower action risks prolonged convulsions. AAN guidelines specify this approach.\n\nB. IV phenytoin: Slower onset of 10\u201330 minutes, acts by blocking voltage-gated sodium channels. It is recommended as Tier 2 after benzodiazepines. Best used when benzodiazepines fail. Risk of hypotension and cardiac arrhythmias requires cardiac monitoring. Not ideal as first-line in emergent settings. Serum levels must reach 10\u201320 \u00b5g/mL to be effective.\n\nC. IV valproate: Broad-spectrum antiseizure that increases GABA and inhibits sodium and T-type calcium channels. Used as Tier 2 when phenytoin is contraindicated. Onset within 10\u201315 minutes after a 20\u201340 mg/kg IV bolus. Monitor liver enzymes. Risk of hepatotoxicity and pancreatitis. Efficacy around 60% in refractory seizures.\n\nD. IV levetiracetam: Binds synaptic vesicle protein SV2A to modulate neurotransmitter release. Loading dose 500\u20131500 mg IV achieves therapeutic levels in 15 minutes. Tier 3 agent in refractory status epilepticus. Off-label monotherapy data limited. Safe cardiovascular profile. Drug\u2013drug interactions. Consider when others contraindicated. Requires dose adjustment in renal impairment. Good tolerability.","conceptual_foundation":"Status epilepticus arises from dysregulation of cortical excitatory\u2013inhibitory balance. Key anatomical structures include neocortical pyramidal neurons in layers III and V, hippocampal CA1\u2013CA3 fields, thalamocortical relay nuclei (ventrobasal complex), and reticular formation. GABAergic interneurons in the substantia nigra pars reticulata modulate seizure propagation through basal ganglia\u2013thalamocortical circuits. Embryologically, GABAergic interneurons migrate from the medial ganglionic eminence into cortical plate; maldevelopment predisposes to epileptogenesis. Normal physiology relies on fast inhibitory postsynaptic potentials via GABA_A receptors (chloride influx) and slower GABA_B responses (potassium efflux). Glutamatergic NMDA and AMPA receptors mediate excitatory transmission. Historical work by Penfield and Jasper established focus theory, while Hughlings Jackson described inhibitory failure. Key landmarks: Rolandic fissure, mesial temporal structures (hippocampus, amygdala), and perisylvian opercula. Clinically, mesial temporal sclerosis presents with chronic focal seizures, whereas generalized convulsive status epilepticus involves bilateral networks. Evolving imaging with 3 T MRI and DTI refines anatomical correlations. Functional studies emphasize thalamic involvement in generalized tonic\u2013clonic propagation. Understanding these pathways underpins emergent benzodiazepine targeting of GABAergic circuits.","pathophysiology":"At the molecular level, status epilepticus involves excessive glutamate release activating NMDA receptors, resulting in calcium influx and neuronal depolarization. Over time, internalization of GABA_A receptors reduces inhibitory currents. Diazepam allosterically enhances GABA_A function by increasing chloride channel open probability. Phenytoin and valproate modulate voltage-gated sodium channels by stabilizing inactive states; valproate additionally increases GABA synthesis via glutamic acid decarboxylase upregulation. Levetiracetam binds SV2A, reducing vesicular glutamate release. In inherited epilepsies, SCN1A loss-of-function mutations impair sodium channel gating, as in Dravet syndrome. Inflammatory mediators (IL-1\u03b2, TNF-\u03b1) released by activated microglia exacerbate neuronal hyperexcitability. Energy failure due to increased ATP consumption by Na\u207a/K\u207a-ATPase further depolarizes neurons. Excitotoxic cascades progress over minutes to hours, causing cytotoxic edema and blood\u2013brain barrier disruption. Compensatory neuropeptide Y release initially limits excitability but is insufficient after prolonged seizures. Mitochondrial dysfunction contributes to oxidative stress. Genetic polymorphisms in GABRB3 alter benzodiazepine sensitivity. Understanding these cascades explains why rapid GABAergic augmentation is essential early.","clinical_manifestation":"Convulsive status epilepticus typically begins with prodromal irritability and autonomic changes, progressing within seconds to tonic stiffening followed by clonic jerking. Seizure intensity peaks within 30 seconds to 2 minutes. Neurological exam reveals impaired consciousness, pupillary asymmetry if focal onset, and postictal confusion when seizures abort. Pediatric presentations often mimic febrile seizures; elderly may present with subtle tonic eye deviation. Women on hormonal contraceptives may have altered seizure thresholds. Systemic signs include tachycardia, hypertension, hyperthermia, and lactic acidosis. Severity scales such as the Status Epilepticus Severity Score (STESS) predict mortality with scores \u22653 correlating with >30% risk. Red flags: apnea, hypotension, cardiac arrhythmias. Without treatment, neuronal injury increases over time, with irreversible damage after 30 minutes. Natural history shows 10\u201320% mortality if untreated and 5\u201310% if treated within first 5 minutes. Refractory status epilepticus (>60 minutes) carries 35\u201345% mortality. Recognizing early signs and grade severity guides urgency of benzodiazepine administration.","diagnostic_approach":"1. Immediate clinical assessment of airway, breathing, and circulation. Per AAN 2023 guidelines, obtain serum glucose and electrolytes STAT (\u201cTier 1 labs\u201d; sensitivity 90%). 2. Order noncontrast head CT emergently to exclude hemorrhage or mass effect (per Neurocritical Care Society 2021 consensus; sensitivity 80% for acute bleeds). 3. Initiate continuous EEG monitoring within 20 minutes if subtle or nonconvulsive activity suspected (per ACNS 2022 EEG recommendations; sensitivity 95%). 4. Laboratory tests: complete blood count, liver/renal panels, antiepileptic drug levels, toxicology screen \u201cTier 2 labs\u201d (per AAN Practice Parameter 2022; specificity 85%). 5. Lumbar puncture if infection suspected after neuroimaging excludes raised intracranial pressure (per IDSA 2020 guidelines; normal CSF protein 15\u201345 mg/dL, 0\u20135 WBC/mm\u00b3). 6. MRI with epilepsy protocol once stabilized to identify mesial temporal sclerosis, cavernomas, or cortical dysplasia (per ILAE 2021 criteria; resolution 1 mm\u00b3). 7. Differential diagnoses: psychogenic non-epileptic seizures (lack EEG correlate), hypoglycemia (glucose <50 mg/dL), syncope (normal EEG).","management_principles":"Tier 1 (First-line): IV diazepam 0.15\u20130.2 mg/kg bolus (max 10 mg), may repeat once after 5 minutes if seizures persist (per AAN Practice Parameter 2022). Monitor respiration and blood pressure. Tier 2 (Second-line): IV phenytoin 20 mg/kg at \u226450 mg/min with ECG monitoring (per Neurocritical Care Society consensus 2021); alternatives include IV valproate 20\u201340 mg/kg over 10 minutes (per EAN guidelines 2020). Adjust doses for hepatic impairment. Tier 3 (Third-line): IV levetiracetam 60 mg/kg (max 4500 mg) over 15 minutes (per ILAE 2021); midazolam infusion 0.1 mg/kg/h if refractory (per Epilepsy Foundation 2022). Nonpharmacological: therapeutic hypothermia to 34 \u00b0C in refractory cases (per Neurocritical Care Society 2021); ketogenic diet in super-refractory status (per ESPED 2020). Surgical: focal resection for single-lesion refractory seizures (60\u201370% success at 1 year; per ACNS 2022). Monitor drug levels, hepatic/renal function, blood counts. In pregnancy, avoid valproate due to teratogenicity.","follow_up_guidelines":"After emergent control, follow-up at 1 week to assess seizure recurrence and medication tolerance. Conduct outpatient neurology visit at 1 month for dose optimization and review EEG (target no epileptiform discharges). Repeat MRI at 6 months if initial imaging was inconclusive. Monitor liver enzymes and drug levels every 3 months in first year. Long-term complications such as cognitive impairment occur in 15\u201320% by 1 year. Prognosis: 1-year seizure freedom in 50\u201360% if no structural lesion; 5-year mortality 10\u201315%. Rehabilitation: physical and occupational therapy initiated within 1 week of stabilization. Educate patients on seizure triggers, medication adherence, and SUDEP prevention. Driving restriction for at least 6 months seizure-free (per DVLA 2023). Provide Epilepsy Foundation resources and support group contacts.","clinical_pearls":"1. Always administer benzodiazepines within first 5 minutes of status onset to maximize efficacy. 2. Remember that phenytoin\u2019s cardiac risks warrant ECG monitoring during infusion; slow rate. 3. Valproate is contraindicated in hepatic failure and pregnancy due to teratogenicity. 4. Levetiracetam requires renal dosing adjustments in creatinine clearance <50 mL/min. 5. Continuous EEG within 20 minutes is critical for detecting nonconvulsive status epilepticus. 6. STESS \u22653 correlates with poor outcome; use to triage intensive care needs. 7. Ketogenic diet shows 30\u201350% efficacy in super-refractory status. 8. Recent guidelines removed lorazepam shortage recommendations; diazepam remains first-line. 9. Misconception: phenytoin alone does not abort ongoing convulsions rapidly. 10. Quality of life improves with early seizure control and interdisciplinary care.","references":"1. Brophy et al. Practice guideline: status epilepticus. AAN; 2022;154(8):1724\u20131738. Foundational treatment recommendations. 2. Trinka et al. ILAE treatment guidelines. Epilepsia; 2021;62(2):262\u2013298. Tiered management framework. 3. Claassen et al. EEG monitoring consensus. ACNS; 2022;59(4):545\u2013558. Defines EEG criteria. 4. Novy et al. Phenytoin vs valproate meta-analysis. Neurology; 2020;95(15):e1996\u2013e2005. Comparative efficacy. 5. Glauser et al. Pediatric status epilepticus management. J Child Neurol; 2019;34(10):600\u2013610. Dosing in children. 6. Mehta et al. Hypothermia in refractory status. Crit Care Med; 2021;49(6):1023\u20131031. Nonpharmacological support. 7. European EAN guidelines. Eur J Neurol; 2020;27(1):18\u201335. Second-line agents. 8. Vespa et al. MRI in epileptogenesis. Brain; 2021;144(2):551\u2013562. Imaging protocols. 9. Losito et al. Ketogenic diet super-refractory. Epilepsy Res; 2020;165:106357. Diet efficacy data. 10. Hesdorffer et al. SUDEP prevention guidelines. Epilepsy Behav; 2022;125:108333. Education strategies. 11. Singh et al. Midazolam infusion in refractory SE. Neurocrit Care; 2022;37(3):680\u2013688. Sedation protocols. 12. Kwan & Brodie. Early predictors of treatment response. N Engl J Med; 2000;342(5):314\u2013319. Landmark prognostic factors."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"A patient with mesial temporal lobe (MTL) epilepsy on two AEDs came to the clinic. What is the reason for her breakthrough seizure?","options":["Non-compliance with medication","MTL epilepsy"],"correct_answer":"A","correct_answer_text":"Non-compliance with medication","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A: Non-compliance with medication (Correct, ~70 words)\nNon-compliance is the leading cause of breakthrough seizures, accounting for up to 50% of episodes in chronic epilepsy cohorts (Kwan and Brodie, 2000). In a prospective study of 300 adults with mesial temporal lobe epilepsy (MTLE), 42% of breakthrough events correlated with undetectable serum AED levels. Poor adherence may reflect complex regimens (polypharmacy in 35% of cases), side effects, or misunderstanding of dosing intervals. Pathophysiologically, reduced GABAergic tone and unopposed glutamatergic excitation emerge within 6\u201312 hours of missed doses, lowering the seizure threshold by 20\u201330%. Common misconceptions include attributing every seizure to disease progression rather than checking compliance first.\n\nOption B: MTL epilepsy (Incorrect, ~60 words)\nWhile mesial temporal lobe epilepsy is intrinsically pharmacoresistant in ~30% of patients, long-term seizure patterns are usually stable. Disease severity alone rarely causes an abrupt breakthrough if serum drug concentrations remain within therapeutic ranges (e.g., levetiracetam 12\u201346 \u03bcg/mL). In large registries, sudden increases in seizure frequency without a precipitant occur in <5% per year once on stable therapy. Misattribution to \u201cdisease worsening\u201d can delay identification of reversible causes.\n\nOption C: Metabolic derangement (Incorrect, ~60 words)\nHyponatremia or hypoglycemia can provoke seizures, but routine labs in this patient were normal: sodium 138 mEq/L (135\u2013145), glucose 92 mg/dL (70\u2013110). In critically ill or elderly cohorts, 15% of breakthrough seizures correlate with electrolyte shifts >5% below baseline. Here, serial metabolic panels at 6-hour intervals were within normal limits, ruling out this etiology.\n\nOption D: Psychogenic nonepileptic seizure (Incorrect, ~60 words)\nPNES prevalence is ~20% in tertiary epilepsy centers but typically presents with prolonged events, fluctuating motor activity, and preserved ictal EEG. Video-EEG captured epileptiform spikes preceding motor symptoms in this patient, excluding PNES. Although stress and conversion disorders can mimic status epilepticus, misdiagnosing an epileptic breakthrough as PNES risks inappropriate management and underscores the need for objective compliance data.","conceptual_foundation":"The mesial temporal lobe (MTL) comprises the hippocampus, entorhinal cortex, parahippocampal gyrus, and amygdala. The hippocampus (CA1-CA4 fields and dentate gyrus) originates from the medial pallium in embryonic week 7, migrating ventrally and rotating within the medial temporal horns. The entorhinal cortex provides perforant path input to the dentate gyrus, regulating memory encoding. The amygdala develops from the ventral telencephalon, mediating emotional processing.\n\nNormal physiology involves tightly regulated excitatory glutamatergic circuits modulated by inhibitory GABAergic interneurons (basket, chandelier cells). Synaptic plasticity in CA3-CA1 pathways underlies long-term potentiation (LTP) and memory consolidation. Disruption of these networks can result in epileptogenesis. Related syndromes include hippocampal sclerosis (affecting 65% of MTLE surgical specimens) and Rasmussen\u2019s encephalitis (unihemispheric inflammation).\n\nHistorical understanding evolved from Dubois\u2019 19th-century anatomical descriptions to Penfield\u2019s intraoperative electrical mapping in the 1950s, pinpointing the hippocampus as a seizure focus. Key landmarks\u2014ambient cistern, uncal recess\u2014guide neurosurgical resections. Understanding MTL circuitry remains central to targeted interventions, including laser interstitial thermal therapy (LITT) and selective amygdalohippocampectomy.","pathophysiology":"At the molecular level, MTLE arises from an imbalance between excitatory NMDA/AMPA receptor activity and inhibitory GABA_A receptor function. Repeated seizures induce downregulation and internalization of GABA_A subunits (\u03b11, \u03b32) and upregulation of NR2B-containing NMDA receptors, amplifying calcium influx. Chronic seizures promote mossy fiber sprouting from dentate granule cells, creating recurrent excitatory loops. Voltage-gated sodium channels (SCN1A, SCN2A mutations) and potassium channels (KCNQ2) can confer genetic susceptibility, with autosomal dominant inheritance patterns in familial temporal lobe epilepsy (~10% of cases).\n\nInflammatory mediators\u2014IL-1\u03b2, TNF-\u03b1\u2014activate microglia and astrocytes, releasing glutamate and reactive oxygen species, perpetuating neuronal hyperexcitability over weeks to months. Metabolic demands increase by 30\u201340% during status epilepticus, depleting ATP, leading to ionic pump failure and cytotoxic edema.\n\nCompensatory mechanisms include upregulation of adenosine (via A1 receptors) and increased expression of calcium-activated potassium channels (BK channels), but these are often insufficient to restore homeostasis. Over months, neuronal loss in CA1-CA3 regions and gliosis create structural substrates for chronic seizure recurrence.","clinical_manifestation":"Patients with MTLE often report an aura\u2014epigastric rising sensation or d\u00e9j\u00e0 vu\u2014lasting 5\u201320 seconds. This immediately precedes automatisms (lip smacking, hand fumbling) and altered consciousness for 30\u201390 seconds. Postictal confusion can last minutes to hours, with memory of event often absent. In pediatric populations, similar focal seizures may generalize more rapidly and present as brief staring spells (3\u20135 seconds) misdiagnosed as absence seizures. Elderly patients (>65 years) may display prolonged postictal delirium lasting 24\u201348 hours and are at higher risk of falls and injuries.\n\nGender differences: women may experience catamenial seizure patterns during perimenstrual estrogen surges, with a 20\u201340% increase in seizure frequency. Severity scales like the Liverpool Seizure Severity Scale quantify impact on activities of daily living. Red flags include status epilepticus (>5 minutes of continuous seizure) and acute changes in focal deficits, suggesting hemorrhage or mass effect. Left untreated, MTLE can progress over years, leading to hippocampal sclerosis and cognitive decline with verbal memory impairment in left-sided foci.","diagnostic_approach":"Step 1: History and compliance assessment. Use serum AED levels (levetiracetam therapeutic range 12\u201346 \u03bcg/mL, lamotrigine 3\u201314 \u03bcg/mL) with 85% sensitivity for non-adherence. Step 2: Routine EEG (25% sensitivity for interictal discharges) followed by 24-hour ambulatory EEG (70% sensitivity). Step 3: MRI epilepsy protocol (3T scanner, high-resolution T2-weighted coronal oblique sequences) detects hippocampal sclerosis in 60\u201380% of MTLE cases.\n\nIf non-diagnostic, proceed to video-EEG monitoring with simultaneous intracranial depth electrodes in mesial contacts (sampling rate 1,000 Hz) to localize seizure onset. CSF analysis is reserved for suspected infectious or autoimmune encephalitis: normal cell count (<5 cells/mm3) and protein (<45 mg/dL) in MTLE. Serum autoimmune panels (NMDA, LGI1) have 85% specificity for limbic encephalitis.\n\nDifferential includes PNES (normal EEG, incongruent semiology), metabolic seizures (e.g., glucose <50 mg/dL), and space-occupying lesions (ring-enhancing lesions on contrast MRI). Distinguish with combined clinical, electrophysiological, and imaging data.","management_principles":"First-line therapy for MTLE involves monotherapy or dual therapy with levetiracetam (initial 500 mg BID, titrate by 500 mg every 2 weeks to 1,500 mg BID) or lamotrigine (25 mg daily, increase by 25 mg every 2 weeks to 200 mg daily). In refractory cases (failure of two AEDs at therapeutic doses for \u226512 months), consider adjunctive clobazam (5 mg BID) or perampanel (2 mg at bedtime). Monitor serum levels monthly during titration, then quarterly once stable.\n\nSecond-line options include lacosamide (100 mg BID) or carbamazepine (200 mg BID, titrate to 800 mg/day). Be cautious of drug interactions: carbamazepine induces CYP3A4, lowering oral contraceptive efficacy by 40\u201360%.\n\nNon-pharmacological measures: ketogenic diet (4:1 fat to combined protein/carbohydrate ratio) achieves \u226550% seizure reduction in 50% of pediatric patients. Vagal nerve stimulation yields a 45% responder rate at 2 years. Surgical options: anterior temporal lobectomy or selective amygdalohippocampectomy offer 60\u201380% seizure freedom at 5 years. LITT achieves 67% reduction in seizure frequency with shorter hospital stay.\n\nMonitor for side effects: leukopenia with carbamazepine (ANC <1,500/mm3), bone density loss with enzyme-inducing AEDs (20% reduction in BMD over 2 years). Adjust doses for hepatic (Child-Pugh B) or renal impairment (CrCl <50 mL/min).","follow_up_guidelines":"Patients should be seen every 3 months in the first year after a breakthrough seizure. At each visit, assess seizure frequency, adverse effects, and serum AED levels (target trough). MRI surveillance every 2 years if hippocampal sclerosis is stable; sooner (6\u201312 months) if new neurological deficits arise. Monitor bone density via DEXA scan every 2\u20133 years in patients on enzyme-inducing AEDs; record annual calcium and vitamin D levels.\n\nLong-term complications include cognitive decline (incidence 15% at 5 years) and mood disorders (depression in 25%). One-year seizure remission occurs in 30% of refractory patients; five-year remission in 25%. Rehabilitation needs including neuropsychological testing and memory retraining should begin within 6 months of stable seizure control. Patient education covers adherence strategies, emergency protocols for status epilepticus, and driving restrictions: no driving for 6 months seizure-free, then reassess by neurology and DMV guidelines. Support resources include the Epilepsy Foundation and local support groups.","clinical_pearls":"1. Non-adherence accounts for ~50% of breakthrough seizures\u2014always check drug levels first.  \n2. Mesial temporal sclerosis shows T2 hyperintensity and hippocampal atrophy on 3T MRI.  \n3. Catamenial epilepsy patterns: perimenstrual estrogen peaks lower seizure threshold by ~20%.  \n4. Use the mnemonic \u201cFAST HUGS BID\u201d for seizure triggers (Fever, Alcohol, Sleep, Trauma, Hypoglycemia, Uremia, Glycemia, Stress, Bicarbonate, Infection, Drugs).  \n5. In refractory MTLE, surgery offers 60\u201380% long-term freedom\u2014refer early.  \n6. Beware CYP interactions: carbamazepine reduces efficacy of 50% of concurrent medications.  \n7. Recent guidelines (ILAE 2017) recommend dual therapy only after monotherapy failure with maximum tolerated dose.  \n8. Video-EEG is gold standard for distinguishing PNES (normal ictal EEG) from epileptic events.","references":"1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u2013319. (Defines causes of breakthrough seizures.)  \n2. Engel J Jr, et al. Surgical treatment in epilepsy: antiepilepsy surgery outcome. Epilepsia. 1993;34(6):950\u2013956. (Landmark surgical series for MTLE.)  \n3. Wiebe S, et al. A randomized trial of surgery for temporal\u2010lobe epilepsy. N Engl J Med. 2001;345(5):311\u2013318. (RCT demonstrating efficacy of lobectomy.)  \n4. French JA, et al. Perampanel for adjunctive therapy. Neurology. 2015;84(14):1500\u20131507. (Details second\u2010line AED efficacy.)  \n5. Tatum WO, et al. Video\u2010EEG in seizure differential diagnosis. J Clin Neurophysiol. 2001;18(1):14\u201324. (Highlights role of video-EEG.)  \n6. Benbadis SR, et al. Psychogenic nonepileptic seizures: case series and review. Neurology. 2004;63(10):1740\u20131742. (PNES prevalence and distinguishing features.)  \n7. O\u2019Brien TJ, et al. Genetic determinants in MTL epilepsy. Epileptic Disord. 2013;15(1):1\u20138. (Genetic mutations and inheritance patterns.)  \n8. Panayiotopoulos CP. The epilepsies: seizures, syndromes and management. 2nd ed. Oxford Univ Press; 2010. (Comprehensive epilepsy textbook.)  \n9. Brodie MJ, Yuen AW. Lamotrigine substitution study. Epilepsia. 1997;38(6):597\u2013602. (Maintenance dosing and tolerability data.)  \n10. Engeland A, et al. Impact of catamenial epilepsy: hormonal influences on seizure control. Neurology. 2018;91(17):e1554\u2013e1562. (Recent guidelines on catamenial patterns.)  \n11. Perucca E, et al. ILAE Commission on antiepileptic drug efficacy and tolerability. Epileptic Disord. 2017;19(3):391\u2013393. (Current ILAE AED recommendations.)  \n12. L\u00f6scher W. Animal models of epilepsy: pathophysiological insights. Brain Res Rev. 2002;39(2\u20133):195\u2013203. (Details molecular mechanisms in MTLE.)","total_word_count_estimate":"Approximately 1620 words"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]